Department of Ophthalmology, Aksaray University Faculty of Medicine, Aksaray, Turkey.
Department of Dermatology, Aksaray University Faculty of Medicine, Aksaray, Turkey.
Int Ophthalmol. 2022 Jul;42(7):2071-2078. doi: 10.1007/s10792-021-02205-1. Epub 2022 Jan 3.
The aim of this pilot study was to quantify the meibography changes in patients administered with oral isotretinoin.
This prospective pilot study included 30 eyes of 30 patients who received oral isotretinoin treatment due to acne. Each patient underwent a general ophthalmological examination. After fluorescence staining of the ocular surface, the tear film break-up time (TFBUT) test, meibography and Schirmer test were carried out and noted. All of these procedures were applied before the treatment and repeated at 1, 3, and 6 months after the treatment.
The percentage of upper meibomian gland (MG) loss at 3 and 6 months after the treatment was 22.2% (p = 0.001) and 23.6% (p = 0.001), respectively. The percentage of lower MG loss at 3 and 6 months after the treatment was 18.7% (p = 0.001) and 20.7% (p = 0.001), respectively. The corneal fluorescein staining score at 3 and 6 months after treatment was 0.57 (p = 0.001), and 0.47 (p = 0.012), respectively.
These findings show that oral isotretionin treatment may affect MG morphology. The study findings also suggest that isotretinoin may cause tear film instability with Meibomian gland dysfunction and may cause evaporative type of dryness.
本研究旨在量化接受口服异维 A 酸治疗的患者的睑板腺照相变化。
这是一项前瞻性的初步研究，纳入了 30 例因痤疮接受口服异维 A 酸治疗的患者的 30 只眼。每位患者均接受了全面的眼科检查。在对眼表面进行荧光染色后，进行泪膜破裂时间（TFBUT）试验、睑板腺照相和泪液分泌试验，并记录结果。所有这些程序均在治疗前进行，并在治疗后 1、3 和 6 个月重复进行。
治疗后 3 个月和 6 个月时，上睑板腺（MG）丧失的百分比分别为 22.2%（p=0.001）和 23.6%（p=0.001）。治疗后 3 个月和 6 个月时，下睑板腺丧失的百分比分别为 18.7%（p=0.001）和 20.7%（p=0.001）。治疗后 3 个月和 6 个月时的角膜荧光素染色评分分别为 0.57（p=0.001）和 0.47（p=0.012）。
这些发现表明，口服异维 A 酸治疗可能会影响 MG 形态。研究结果还表明，异维 A 酸可能会导致泪膜不稳定和睑板腺功能障碍，引起蒸发型干燥。
